Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / July 31, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Phathom Pharmaceuticals, Inc. ("Phathom" or "the Company") (NASDAQ:PHAT). Investors who purchased Phathom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PHAT.

Phathom Investigation Details

Phathom announced second quarter 2026 financial results and lowered its full-year 2026 net revenue guidance to $300 million to $325 million, down from the $320 million to $345 million range that the Company had reaffirmed on its February 26, 2026 fourth quarter 2025 earnings call and again on its April 30, 2026 first quarter 2026 earnings call. On the February 26 call, President and Chief Executive Officer Steve Basta stated, "Our $320 million to $345 million revenue guidance for 2026 reflects our operating expectation of continued solid growth from our GI-focused strategy." On the April 30 call, Chief Financial Officer Sanjeev Narula told investors, "We continue to anticipate 2026 net revenue between $320 million to $345 million," while Mr. Basta added, "We are thus maintaining our revenue guidance for the year." During that same call, Mr. Basta also stated, "We have more than 290 reps in place to start Q2," and Mr. Narula represented that the Company's gross-to-net discount was tracking at the lower end of its expected range. Following this news, Phathom stock price dropped.

What's Next for Phathom Investors?

If you are aware of any facts relating to this investigation or purchased Phathom securities, you can assist this investigation by visiting the firm's site: bgandg.com/PHAT. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Phathom Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Phathom Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC